European Prostate Cancer Awareness Day 17 November 2020





Prof. Jelle Barentsz

Radboudumc Prostate MRI Reference Center

WHATIS MUII-PARAMETRIC MR





Prostate MRI = multi-parametric MRI



T2-Weighted Imaging (T2W)

ANATOMY: T2W





ANATOMY: T2W



Lower SI: PCa + hematoma + prostatitis + BPH

Prostate MRI = multi-parametric MRI


ANATOMY

T2-Weighted Imaging (T2W)


BIOLOGY

Diffusion Weighed Imaging (DWI)


BIOLOGY (Cell Density): DWI




Glandular tissue Gleason 1-2: low-grade




Cell Density: DWI




Glandular tissue Gleason 1-2: low-grade






Tightly packed cells Gleason 5: high-grade





Cell Density: DWI







Glandular tissue Gleason 1-2: low-grade







Tightly packed cells Gleason 5: high-grade



Prostate MRI = multi-parametric MRI

ANATOMY

T2-Weighted Imaging (T2W)


BIOLOGY

Diffusion Weighed Imaging (DWI)


VASCULARITY

Dynamic Contrast enhanced

VASCULARITY: T2W



VASCULARITY: T2W



WHY PROSTATE MRI?







Cochrane Database of Systematic Reviews

Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer (Review)

Drost FJH, Osses DF, Nieboer D, Steyerberg EW, Bangma CH, Roobol MJ, Schoots IG

Drost FJH, Osses DF, Nieboer D, Steyerberg EW, Bangma CH, Roobol MJ, Schoots IG.

Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer.

Cochrane Database of Systematic Reviews 2019, Issue 4. Art. No.: CD012663.

DOI: 10.1002/J4651888.CD012663.pub2.

33% avoid biopsy



Cochrane Database of Systematic Reviews

Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer (Review)

Drost FJH, Osses DF, Nieboer D, Steyerberg EW, Bangma CH, Roobol MJ, Schoots IG

Drost F.JH, Osses DF, Nieboer D, Steyerberg EW, Bangma CH, Roobol MJ, Schoots IG.

Prostate MRI, with or without MBI-targeted biopsy, and systematic biopsy for detecting prostate cancer.

Cochrane Database of Systematic Reviews 2019, Issue 4. Art. No.: CD012663.

DOI: 10.1002/J4651858.CD012663.pub2.

miss 8%





Cochrane Database of Systematic Reviews

Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer (Review)

Drost FJH, Osses DF, Nieboer D, Steyerberg EW, Bangma CH, Roobol MJ, Schoots IG

Drost F.JH, Osses DF, Nieboer D, Steyerberg EW, Bangma CH, Roobol MJ, Schoots IG.

Prostate MRI, with or without MBI-targeted biopsy, and systematic biopsy for detecting prostate cancer.

Cochrane Database of Systematic Reviews 2019, Issue 4. Art. No.: CD012663.

DOI: 10.1002/J4651858.CD012663.pub2.

miss 8%



Cochrane Database of Systematic Reviews

Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer (Review)

Drost FJH, Osses DF, Nieboer D, Steyerberg EW, Bangma CH, Roobol MJ, Schoots IG

Drost F.J.H., Osses DF, Nieboer D, Steyerberg EW, Bangma CH, Roobol MJ, Schoots IG.

Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer.

Cochrane Potabose of Systematic Reviews 2019, Issue 4. Art. No.: CD012663.

DOI: 10.1007/LASSES SYSTEM 2019263-11.

33% avoid biopsy

reduced overdiagnosis (28% → 17%)

miss 8%



Cochrane Database of Systematic Reviews

Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer (Review)

Drost FJH, Osses DF, Nieboer D, Steyerberg EW, Bangma CH, Roobol MJ, Schoots IG

Drost FJH, Osses DF, Nielboer D, Steyerberg EW, Bangma CH, Roobol MJ, Schoots IG.

Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer.

Cochrane Database of Systematic Reviews 2019, Issue 4. Art. No.: CD012663.

DOI: 10.1002/14651858.CD012663.pub2.

33% avoid biopsy

reduced overdiagnosis (28% → 17%)

equal significant cancers (28% → 29%)

"4M" Nijmegen

Head-to-Head 625 patients

miss 3%

49% avoid biopsy

EUROPEAN UROLOGY 75 (2019) 570-578

available at www.sciencedirect.com journal homepage: www.europeanurology.com



European Association of Urology

Platinum Priority – Prostate Cancer – Editor's Choice
Editorial by Derek J. Rosario, Thomas J. Walton and Steven J. Kennish on pp. 579–581 of this issue


Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study

Marloes van der Leest^a, Erik Cornel^b, Bas Israël^a, Rianne Hendriks^c, Anwar R. Padhani^d, Martijn Hoogenboom^a, Patrik Zamecnik^a, Dirk Bakker^b, Anglita Yanti Setiasti^e, Jeroen Veltman^f, Huib van den Hout^f, Hans van der Lelij^g, Inge van Oort^c, Sjoerd Klaver^h, Frans Debruyne^f, Michiel Sedelaar^c, Gerjon Hannink^f, Maroeska Rovers^f, Christina Hulsbergen-van de Kaa^{e,†}, Jelle O. Barentsz^{a,†,*}

reduced overdiagnosis (25% → 14%)

equal significant cancers (23% → 25%)


EAU guidelines 2019



Perform prostate-MRI before biopsy

ROLE OF MIRIIN EARLY DETECTION?










PSA **Eindresultaat R**C 55 % MRI Prostate: PSA, FPSA and ratio Mannogram





Challenges

Optimize reading: PI-RADS

Eur Radiol (2012) 22:746–757 DOI 10.1007/s00330-011-2377-y

UROGENITAL

ESUR prostate MR guidelines 2012

Jelle O. Barentsz · Jonathan Richenberg · Richard Clements · Peter Choyke · Sadhna Verma · Geert Villeirs · Olivier Rouviere · Vibeke Logager · Jurgen J. Fütterer



Challenges

- Reduce workload: structured report
- Maintain/improve image quality: QC

European Radiology (2020) 30:5404–5416 https://doi.org/10.1007/s00330-020-06929-z

UROGENITAL

Check fo updates
quality
ogists'


ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists' training


Maarten de Rooij 1 • Bas Israël 1,2 • Marcia Tummers 3 • Hashim U. Ahmed 4,5 • Tristan Barrett 6 • Francesco Giganti 7,8 • Bernd Hamm 9 • Vibeke Løgager 10 • Anwar Padhani 11 • Valeria Panebianco 12 • Philippe Puech 13 • Jonathan Richenberg 14 • Olivier Rouvière 15,16 • Georg Salomon 17 • Ivo Schoots 18,19 • Jeroen Veltman 20 • Geert Villeirs 21 • Jochen Walz 22 • Jelle O. Barentsz 1














PROSTAGRAM

€95 10'





If we want to prevent the harm of No or Opportunistic Screening.....



MyTest Prostaat

Zelftest voor de bepaling van het PSA-gehalte

- Controleer uit voorzorg of bij klachten uw prostaat
- Uitslag bekend na 5 minuten
- Eenvoudige bloedtest





We need to set up an Early **Detection Program in the EU** with Risk-Calculators and MRI



and mortality rate of the most frequent cancer in men

PRIMMED-trial

(PRostate cancer Informed Men MRi Early Detection)

 Standardize and synchronize data within the EU



PRIMMED-trial

(PRostate cancer Informed Men MRi Early Detection)


- Standardize and synchronize data
- Collect one large dataset, freely available



PRIMMED-trial

(PRostate cancer Informed Men MRi Early Detection)

- Standardize and synchronize data
- Collect one large dataset, freely available
- Set-up a multi-country prospective trial



Is Early Detection of PCa now possible?



www.mri-prostate-barentsz.nl

Jelle Barentsz

For Questions?

jelle.barentsz@radboudumc.nl

